Questions Persist On Lilly’s Tirzepatide And Tolerability

Concerns about gastrointestinal tolerability continue to weigh on Lilly’s tirzepatide, despite improvements seen in a Phase II dose-escalation study. Lilly believes the adverse events are manageable.